Search Results for "Colchicine And Rivaroxaban"

09:21 EST 19th February 2017 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Optimal dosing of rivaroxaban is undefined

The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the....

Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.

Treatment with colchicine is not linked to reducing cardiovascular mortality

An evidence review of 39 clinical trials found that patients who received continuous long-term treatment with colchicine had no reduction in all-cause mortality or cardiovascular mortality.

Rivaroxaban for Postoperative DVT of the Lower Limb

Is rivaroxaban a safe and effective approach to postsurgical deep vein thrombosis after extended, but failed, warfarin therapy? Journal of Medical Case Reports

Colchicine and Prevention of Cardiovascular Events

This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials comparing the effects of long-term colchicine treatment with usual care or placebo on cardiovascular events in patients ...

Meta-analysis: Colchicine cuts risk of pericarditis recurrence

(HealthDay)—Colchicine is effective and reduces the risk of pericarditis recurrence/post-pericardiotomy syndrome, according to a meta-analysis published online Aug. 31 in Cardiovascular Therapeutics...

Fewer Major Bleeds on Dabigatran vs Rivaroxaban for AF

In elderly patients with nonvalvular atrial fibrillation (AF), dabigatran and rivaroxaban provide comparable protection against thromboembolic stroke but dabigatran is safer, according to a new analys...

Anakinra for Colchicine-Resistant, Corticosteroid-Dependent Pericarditis

This randomized trial assesses whether anakinra reduces risk of recurrent pericarditis among patients in Italy with colchicine-resistant and corticosteroid-dependent recurrent pericarditis.

Matching PubMed Articles

Potential anticancer role of colchicine-based derivatives: an overview.

Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine i...

Colchicine for prevention and treatment of cardiac diseases: a meta-analysis.

Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...

Prolongation of prothrombin time in the presence of rivaroxaban: is this the only cause?

Rivaroxaban is an oral direct Xa inhibitor that can lead to prolongation of prothrombin time and activated partial thromboplastin time. However, these basic coagulation tests are not specific for the ...

Colchicine in Renal Medicine: New Virtues of an Ancient Friend.

Colchicine is a plant-derived alkaloid that disrupts the cell microtubule system and accumulates in neutrophils, inhibiting neutrophil adhesion and recruitment. Colchicine has been used extensively in...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

Search Whole site using Google

Quick Search
Advertisement Advertisement